Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010

With over 5 years of follow-up, pembrolizumab (Keytruda) continued to demonstrate clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) versus docetaxel among patients with previously treated, advanced non–small cell lung cancer with a PD-L1 tumor proportion score (TPS) of at least 1%, according to updated results from the KEYNOTE-010 study (NCT01905657) presented at the IASLC 2020 World Conference on Lung Cancer.

In an interview with CancerNetwork®, Roy S. Herbst, MD, PhD, of the Yale Cancer Center and Smilow Cancer Hospital, explained what multidisciplinary care teams can take away from this research.

Transcription:

Lung cancer is treated in a multidisciplinary setting; and certainly, if someone is treated in a metastatic setting, we should think about therapy as early as possible. But also, these drugs can now be used in the adjuvant setting. We already know from the PACIFIC trial (NCT02125461) that durvalumab improves survival after chemoradiation. And I’m confident that we’ll see some interesting results soon from some of the Agilent trials in stage I to III disease.

Reference:

Herbst R, Garon E, Kim D, et al. 5-year survival update from KEYNOTE-010: pembrolizumab versus docetaxel in previously treated, PD-L1–positive advanced NSCLC. Presented at the IASLC 2020 World Conference on Lung Cancer. Abstract FP13.01.